A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Part of paid clinical trials in Harrison, New York.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT05607095
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lifileucel (LN-144/LN-145) — BIOLOGICAL
    Lifileucel (LN-144/LN-145) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process. Lifileucel is infused as part of a treatment regimen that includes preparative NMA-LD, followed by one-time autologous TIL infusion, and a short course of high-dose IL-2.

Study Details

This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

Key Dates

Start date
Nov 1, 2022
Status verified
May 2026
Primary completion
May 1, 2027
Completion
May 1, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Participants with Metastatic Uveal Melanoma
    Participants have metastatic uveal melanoma who will undergo surgical excision to generate LN-144/LN-145
  • Experimental: Participants with Metastatic Sarcoma
    Participants have metastatic sarcoma who will undergo surgical excision to generate LN-144/LN-145

Primary Outcome Measure

Adverse events as evaluated by CTCAE v5.0 [ Time Frame: Up to 3 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering WestchesterHarrisonNew York10604
Alexander Shoushtari, MD
646-888-4161
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Alexander Shoushtari, MD
646-888-4161

Find similar trials in Harrison, NY

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Memorial Sloan Kettering Westchester· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies